Metagenomi Therapeutics (MGX) Net Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Net Margin of -1847.68% for Q1 2026, down 1240.96 percentage points from -606.71% a year earlier and down 1271.66 percentage points from the prior quarter.
Powered by 
Analysis
Metagenomi Therapeutics (MGX) Net Margin (2023 - 2026) Analysis & Trends
Over the twelve months ended Mar 31, 2026, Metagenomi Therapeutics' Net Margin came in at -384.61%, down 212.40 percentage points year-over-year; for FY2025, it was -348.54%, down 199.28 percentage points from FY2024.
- By year, Net Margin came in at -149.26% in FY2024 (+3.24 pp) and -152.50% in FY2023.
- The Q1 2026 figure ranks as the lowest quarterly Net Margin in data going back to Q1 2023.
- Year over year, Net Margin has now declined in each of the last seven quarters, with an average year-over-year change of -279.63 percentage points over the last eight quarters.
- The high point for year-over-year Net Margin in five years was Q2 2024 (a gain of 61.07 percentage points); the low point was Q1 2026 (a drop of 1240.96 percentage points).
- Per Business Quant data, the three quarters before Q1 2026 came in at -576.02% (Q4 2025), -235.51% (Q3 2025) and -233.85% (Q2 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 30.88% |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 0.83% |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | 21.27% |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | -8.04% |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 22.65% |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 16.30% |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 23.62% |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | -134.51% |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | -1.65% |
| 10 | Metagenomi Therapeutics | 30.98 Mn | -574.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,847.68% |
| Dec 31, 2025 | -576.02% |
| Sep 30, 2025 | -235.51% |
| Jun 30, 2025 | -233.85% |
| Mar 31, 2025 | -606.71% |
| Dec 31, 2024 | -243.37% |
| Sep 30, 2024 | -163.04% |
| Jun 30, 2024 | -53.67% |
| Mar 31, 2024 | -225.36% |
| Dec 31, 2023 | -155.61% |
| Sep 30, 2023 | -160.32% |
| Jun 30, 2023 | -114.74% |
| Mar 31, 2023 | -186.36% |
API Access
Metagenomi Therapeutics Net Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-margin&ticker=MGX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-margin", "ticker": "MGX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-margin&ticker=MGX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();